FXR expression in rats of hilar cholangiocarcinoma

The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimenta...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 8741 - 7
Main Authors Zhang, Meng-yu, Luo, Ming, Wang, Jie-ping
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.05.2022
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.
AbstractList The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.
The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.
The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.
Abstract The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.
ArticleNumber 8741
Author Wang, Jie-ping
Zhang, Meng-yu
Luo, Ming
Author_xml – sequence: 1
  givenname: Meng-yu
  surname: Zhang
  fullname: Zhang, Meng-yu
  organization: Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University
– sequence: 2
  givenname: Ming
  surname: Luo
  fullname: Luo, Ming
  organization: Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University
– sequence: 3
  givenname: Jie-ping
  surname: Wang
  fullname: Wang, Jie-ping
  email: 3529901542@qq.com
  organization: Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35610302$$D View this record in MEDLINE/PubMed
BookMark eNp9kkFvFSEUhYmpsbX2D7gwk7hxMwoXmIGNiWmsNmliYjRxRxjm8h4v8-AJ86z-e2mn1baLsoHAOV9OLuc5OYgpIiEvGX3LKFfvimBSq5YCtAyUpO3lE3IEVMgWOMDBnfMhOSllQ-uSoAXTz8ghl12FUDgicPbja4O_dxlLCSk2ITbZzqVJvlmHyebGrdNk4yokZ7MLMW3tC_LU26ngyc1-TL6fffx2-rm9-PLp_PTDReukoHPrRia591r2bATnpVd8pOiE4lZIFF71ziJqD0wOg9WoLWcDYxQQBEXF-DE5X7hjshuzy2Fr8x-TbDDXFymvjM1zcBOajkre9dyxQY_CUrCDQtd7SQcArTWvrPcLa7cftjg6jHO20z3o_ZcY1maVfhnNOJW0q4A3N4Ccfu6xzGYbisOpzgbTvhjoOi0psF5W6esH0k3a51hHdaVSslOc06p6dTfRvyi3X1MFahG4nErJ6I0Ls53rJ9WAYTKMmqsimKUIphbBXBfBXFYrPLDe0h818cVUqjiuMP-P_YjrL_LTxGY
CitedBy_id crossref_primary_10_4110_in_2023_23_e6
crossref_primary_10_1002_iid3_727
Cites_doi 10.1093/toxsci/kfz088
10.1016/j.lpm.2018.06.012
10.1245/s10434-021-11109-4
10.1002/jso.25722
10.3389/fphar.2019.00522
10.5009/gnl15568
10.1007/s10822-017-0021-x
10.1016/j.ejso.2017.04.001
10.1016/j.jhep.2018.06.022
10.1080/13543776.2018.1527906
10.12998/wjcc.v8.i1.68
10.1248/bpb.b18-00028
10.1053/j.gastro.2020.07.036
10.1172/JCI88893
10.1016/j.jpha.2019.04.004
10.1016/j.bbrc.2020.04.075
10.1097/MD.0000000000012025
10.1039/c9mt00274j
10.1007/164_2019_232
10.1159/000491715
10.1016/j.bbalip.2020.158733
10.1016/j.bbadis.2017.08.016
10.1371/journal.pone.0210077
10.1124/dmd.113.054304
10.1016/j.soc.2019.06.003
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-12850-w
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
PML(ProQuest Medical Library)
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

Publicly Available Content Database
CrossRef
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 7
ExternalDocumentID oai_doaj_org_article_6053673c1b9d4a02ab8ec7f50b229993
PMC9130506
35610302
10_1038_s41598_022_12850_w
Genre Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-cd153ff9571d2cf5f83d0ec483a45e4f87caee9f215bba9e9a31b1102e240e813
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:31:40 EDT 2025
Thu Aug 21 18:21:43 EDT 2025
Fri Jul 11 06:26:36 EDT 2025
Wed Aug 13 08:19:50 EDT 2025
Wed Feb 19 02:26:09 EST 2025
Tue Jul 01 04:16:31 EDT 2025
Thu Apr 24 23:12:00 EDT 2025
Fri Feb 21 02:40:22 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-cd153ff9571d2cf5f83d0ec483a45e4f87caee9f215bba9e9a31b1102e240e813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-12850-w
PMID 35610302
PQID 2668568330
PQPubID 2041939
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_6053673c1b9d4a02ab8ec7f50b229993
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9130506
proquest_miscellaneous_2669502175
proquest_journals_2668568330
pubmed_primary_35610302
crossref_citationtrail_10_1038_s41598_022_12850_w
crossref_primary_10_1038_s41598_022_12850_w
springer_journals_10_1038_s41598_022_12850_w
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-24
PublicationDateYYYYMMDD 2022-05-24
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-24
  day: 24
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Xiong (CR20) 2019; 10
Di Matteo (CR22) 2019; 14
Shinohara, Fujimori (CR26) 2020; 527
Lv (CR23) 2018; 48
Wang (CR8) 2018; 97
Gao (CR9) 2021; 16
Anderson, Doyle (CR2) 2019; 28
Gege, Hambruch, Hambruch, Kinzel, Kremoser (CR19) 2019; 256
Yang, Takeuchi, Tsuneyama, Tsuyoshi, Shingo (CR17) 2019; 170
Blechacz (CR1) 2017; 11
Celotti (CR7) 2017; 43
Jain, Grandits, Richter, Ecker (CR27) 2017; 31
Lu (CR10) 2019; 120
Preidis, Kim, Moore (CR5) 2017; 127
Ramos Pittol (CR6) 2020; 159
Köck (CR16) 2014; 42
Carino (CR25) 2020; 185
Zheng, Wang, Song, Ye, Xiang (CR14) 2019; 9
Barberis, Rossi, Filauro (CR13) 2019; 84
Takahashi, Ogra (CR15) 2020; 12
Yang (CR11) 2020; 8
Staub (CR12) 2020; 33
Erice (CR21) 2018; 1864
Toumi (CR29) 2018; 47
Wang, He, Wang, Xu, Hao (CR18) 2018; 28
Ploton (CR24) 2018; 69
Camerlo, Seux, Fara (CR3) 2022; 29
Dar (CR28) 2019; 29
Qu (CR4) 2018; 41
S Shinohara (12850_CR26) 2020; 527
A Barberis (12850_CR13) 2019; 84
XL Xiong (12850_CR20) 2019; 10
S Di Matteo (12850_CR22) 2019; 14
A Carino (12850_CR25) 2020; 185
FL Gao (12850_CR9) 2021; 16
GA Preidis (12850_CR5) 2017; 127
C Gege (12850_CR19) 2019; 256
Y Wang (12850_CR8) 2018; 97
XJ Yang (12850_CR11) 2020; 8
K Takahashi (12850_CR15) 2020; 12
S Jain (12850_CR27) 2017; 31
N Toumi (12850_CR29) 2018; 47
F Yang (12850_CR17) 2019; 170
H Wang (12850_CR18) 2018; 28
FS Dar (12850_CR28) 2019; 29
O Erice (12850_CR21) 2018; 1864
K Köck (12850_CR16) 2014; 42
JM Ramos Pittol (12850_CR6) 2020; 159
B Anderson (12850_CR2) 2019; 28
M Ploton (12850_CR24) 2018; 69
A Celotti (12850_CR7) 2017; 43
B Blechacz (12850_CR1) 2017; 11
J Lu (12850_CR10) 2019; 120
X Qu (12850_CR4) 2018; 41
B Lv (12850_CR23) 2018; 48
A Camerlo (12850_CR3) 2022; 29
J Staub (12850_CR12) 2020; 33
B Zheng (12850_CR14) 2019; 9
References_xml – volume: 170
  start-page: 95
  year: 2019
  end-page: 108
  ident: CR17
  article-title: Experimental evidence of liver injury by NTCP-inhibiting drugs with a bile salt supplementation in rats
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfz088
– volume: 47
  start-page: 950
  year: 2018
  end-page: 960
  ident: CR29
  article-title: Role of magnetic resonance imaging in preoperative assessement of hilar cholangiocarcinoma
  publication-title: Presse Med.
  doi: 10.1016/j.lpm.2018.06.012
– volume: 29
  start-page: 2407
  year: 2022
  ident: CR3
  article-title: Robotic left hepatectomy extended to caudate lobe and common biliary duct for hilar cholangiocarcinoma
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-021-11109-4
– volume: 120
  start-page: 1341
  year: 2019
  end-page: 1349
  ident: CR10
  article-title: Prognostic significance of mucinous component in hilar cholangiocarcinoma after curative-intent resection
  publication-title: J. Surg. Oncol.
  doi: 10.1002/jso.25722
– volume: 10
  start-page: 522
  year: 2019
  ident: CR20
  article-title: Emodin rescues intrahepatic cholestasis via stimulating FXR/NTCP pathway in promoting the canalicular export of accumulated bile
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2019.00522
– volume: 11
  start-page: 13
  year: 2017
  end-page: 26
  ident: CR1
  article-title: Cholangiocarcinoma: Current knowledge and new developments
  publication-title: Gut Liver
  doi: 10.5009/gnl15568
– volume: 31
  start-page: 507
  year: 2017
  end-page: 521
  ident: CR27
  article-title: Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human NTCP
  publication-title: J. Comput. Aided Mol. Des.
  doi: 10.1007/s10822-017-0021-x
– volume: 29
  start-page: 874
  year: 2019
  end-page: 877
  ident: CR28
  article-title: Outcomes after surgical resection of hilar cholangiocarcinoma
  publication-title: J. Coll. Phys. Surg. Pak.
– volume: 43
  start-page: 1628
  year: 2017
  end-page: 1635
  ident: CR7
  article-title: Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis
  publication-title: Eur. J. Surg. Oncol.
  doi: 10.1016/j.ejso.2017.04.001
– volume: 69
  start-page: 1099
  year: 2018
  end-page: 1109
  ident: CR24
  article-title: The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2018.06.022
– volume: 28
  start-page: 765
  year: 2018
  end-page: 782
  ident: CR18
  article-title: FXR modulators for enterohepatic and metabolic diseases
  publication-title: Expert Opin. Ther. Pat.
  doi: 10.1080/13543776.2018.1527906
– volume: 8
  start-page: 68
  year: 2020
  end-page: 75
  ident: CR11
  article-title: Application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of bile hilar duct lake in the operation of hilar cholangiocarcinoma
  publication-title: World J. Clin. Cases
  doi: 10.12998/wjcc.v8.i1.68
– volume: 41
  start-page: 1211
  year: 2018
  end-page: 1218
  ident: CR4
  article-title: Dysregulation of NTCP and MRP2 May play an important role in isoniazid-induced liver injury via the SIRT1/FXR pathway in rats and HepG2 cells
  publication-title: Biol. Pharm. Bull.
  doi: 10.1248/bpb.b18-00028
– volume: 159
  start-page: 1853
  year: 2020
  end-page: 1865
  ident: CR6
  article-title: FXR isoforms control different metabolic functions in liver cells via binding to specific DNA Motifs
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.07.036
– volume: 33
  start-page: 202
  year: 2020
  end-page: 209
  ident: CR12
  article-title: Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: A multicenter international study
  publication-title: Ann. Gastroenterol.
– volume: 127
  start-page: 1193
  year: 2017
  end-page: 1201
  ident: CR5
  article-title: Nutrient-sensing nuclear receptors PPARalpha and FXR control liver energy balance
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI88893
– volume: 9
  start-page: 367
  year: 2019
  end-page: 372
  ident: CR14
  article-title: Pharmacokinetics and enterohepatic circulation of jervine, an antitumor steroidal alkaloid from Veratrum nigrum in rats
  publication-title: J. Pharm. Anal.
  doi: 10.1016/j.jpha.2019.04.004
– volume: 527
  start-page: 49
  year: 2020
  end-page: 55
  ident: CR26
  article-title: Promotion of lipogenesis by PPARgamma-activated FXR expression in adipocytes
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2020.04.075
– volume: 97
  start-page: e12025
  year: 2018
  ident: CR8
  article-title: Effect of preoperative cholangitis on prognosis of patients with hilar cholangiocarcinoma: A systematic review and meta-analysis
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000012025
– volume: 12
  start-page: 241
  year: 2020
  end-page: 248
  ident: CR15
  article-title: Identification of the biliary selenium metabolite and the biological significance of selenium enterohepatic circulation
  publication-title: Metallomics
  doi: 10.1039/c9mt00274j
– volume: 16
  start-page: 678
  year: 2021
  end-page: 685
  ident: CR9
  article-title: Insertion of I-125 seed-loaded stent for inoperable hilar cholangiocarcinoma
  publication-title: Wideochir Inne Tech. Maloinwazyjne
– volume: 256
  start-page: 167
  year: 2019
  end-page: 205
  ident: CR19
  article-title: Nonsteroidal FXR ligands: Current status and clinical applications
  publication-title: Handb. Exp. Pharmacol.
  doi: 10.1007/164_2019_232
– volume: 48
  start-page: 158
  year: 2018
  end-page: 172
  ident: CR23
  article-title: FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting IL-6-induced epithelial-mesenchymal transition
  publication-title: Cell Physiol. Biochem.
  doi: 10.1159/000491715
– volume: 185
  start-page: 158733
  year: 2020
  ident: CR25
  article-title: Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis
  publication-title: Biochim. Biophys. Acta Mol. Cell Biol. Lipids.
  doi: 10.1016/j.bbalip.2020.158733
– volume: 1864
  start-page: 1335
  year: 2018
  end-page: 1344
  ident: CR21
  article-title: Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
  publication-title: Biochim. Biophys. Acta Mol. Basis Dis.
  doi: 10.1016/j.bbadis.2017.08.016
– volume: 14
  year: 2019
  ident: CR22
  article-title: The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0210077
– volume: 42
  start-page: 665
  year: 2014
  end-page: 674
  ident: CR16
  article-title: Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.113.054304
– volume: 28
  start-page: 601
  year: 2019
  end-page: 617
  ident: CR2
  article-title: Surgical considerations of hilar cholangiocarcinoma
  publication-title: Surg. Oncol. Clin. N. Am.
  doi: 10.1016/j.soc.2019.06.003
– volume: 84
  start-page: 245
  year: 2019
  end-page: 247
  ident: CR13
  article-title: Cholangitis mimicking hilar cholangiocarcinoma
  publication-title: Rev. Gastroenterol. Mex.
– volume: 84
  start-page: 245
  year: 2019
  ident: 12850_CR13
  publication-title: Rev. Gastroenterol. Mex.
– volume: 28
  start-page: 601
  year: 2019
  ident: 12850_CR2
  publication-title: Surg. Oncol. Clin. N. Am.
  doi: 10.1016/j.soc.2019.06.003
– volume: 47
  start-page: 950
  year: 2018
  ident: 12850_CR29
  publication-title: Presse Med.
  doi: 10.1016/j.lpm.2018.06.012
– volume: 170
  start-page: 95
  year: 2019
  ident: 12850_CR17
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfz088
– volume: 185
  start-page: 158733
  year: 2020
  ident: 12850_CR25
  publication-title: Biochim. Biophys. Acta Mol. Cell Biol. Lipids.
  doi: 10.1016/j.bbalip.2020.158733
– volume: 97
  start-page: e12025
  year: 2018
  ident: 12850_CR8
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000012025
– volume: 14
  year: 2019
  ident: 12850_CR22
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0210077
– volume: 42
  start-page: 665
  year: 2014
  ident: 12850_CR16
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.113.054304
– volume: 11
  start-page: 13
  year: 2017
  ident: 12850_CR1
  publication-title: Gut Liver
  doi: 10.5009/gnl15568
– volume: 29
  start-page: 2407
  year: 2022
  ident: 12850_CR3
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-021-11109-4
– volume: 31
  start-page: 507
  year: 2017
  ident: 12850_CR27
  publication-title: J. Comput. Aided Mol. Des.
  doi: 10.1007/s10822-017-0021-x
– volume: 127
  start-page: 1193
  year: 2017
  ident: 12850_CR5
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI88893
– volume: 16
  start-page: 678
  year: 2021
  ident: 12850_CR9
  publication-title: Wideochir Inne Tech. Maloinwazyjne
– volume: 159
  start-page: 1853
  year: 2020
  ident: 12850_CR6
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.07.036
– volume: 1864
  start-page: 1335
  year: 2018
  ident: 12850_CR21
  publication-title: Biochim. Biophys. Acta Mol. Basis Dis.
  doi: 10.1016/j.bbadis.2017.08.016
– volume: 10
  start-page: 522
  year: 2019
  ident: 12850_CR20
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2019.00522
– volume: 12
  start-page: 241
  year: 2020
  ident: 12850_CR15
  publication-title: Metallomics
  doi: 10.1039/c9mt00274j
– volume: 69
  start-page: 1099
  year: 2018
  ident: 12850_CR24
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2018.06.022
– volume: 29
  start-page: 874
  year: 2019
  ident: 12850_CR28
  publication-title: J. Coll. Phys. Surg. Pak.
– volume: 527
  start-page: 49
  year: 2020
  ident: 12850_CR26
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2020.04.075
– volume: 33
  start-page: 202
  year: 2020
  ident: 12850_CR12
  publication-title: Ann. Gastroenterol.
– volume: 256
  start-page: 167
  year: 2019
  ident: 12850_CR19
  publication-title: Handb. Exp. Pharmacol.
  doi: 10.1007/164_2019_232
– volume: 9
  start-page: 367
  year: 2019
  ident: 12850_CR14
  publication-title: J. Pharm. Anal.
  doi: 10.1016/j.jpha.2019.04.004
– volume: 48
  start-page: 158
  year: 2018
  ident: 12850_CR23
  publication-title: Cell Physiol. Biochem.
  doi: 10.1159/000491715
– volume: 28
  start-page: 765
  year: 2018
  ident: 12850_CR18
  publication-title: Expert Opin. Ther. Pat.
  doi: 10.1080/13543776.2018.1527906
– volume: 41
  start-page: 1211
  year: 2018
  ident: 12850_CR4
  publication-title: Biol. Pharm. Bull.
  doi: 10.1248/bpb.b18-00028
– volume: 8
  start-page: 68
  year: 2020
  ident: 12850_CR11
  publication-title: World J. Clin. Cases
  doi: 10.12998/wjcc.v8.i1.68
– volume: 43
  start-page: 1628
  year: 2017
  ident: 12850_CR7
  publication-title: Eur. J. Surg. Oncol.
  doi: 10.1016/j.ejso.2017.04.001
– volume: 120
  start-page: 1341
  year: 2019
  ident: 12850_CR10
  publication-title: J. Surg. Oncol.
  doi: 10.1002/jso.25722
SSID ssj0000529419
Score 2.37462
Snippet The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target...
Abstract The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8741
SubjectTerms 692/699/67
692/699/67/70
Alanine
Alanine transaminase
Animal models
Animals
Aspartate transaminase
Bile Duct Neoplasms - pathology
Bile ducts
Bile Ducts, Intrahepatic - pathology
Cholangiocarcinoma
Cholangiocarcinoma - pathology
Drug delivery
Drug development
Gene therapy
Glyceraldehyde-3-phosphate dehydrogenase
Humanities and Social Sciences
Immunohistochemistry
Klatskin Tumor - genetics
Klatskin Tumor - pathology
Male
mRNA
multidisciplinary
Physical activity
Polymerase chain reaction
Rats
Rats, Wistar
Rodents
Science
Science (multidisciplinary)
Therapeutic targets
Transaminase
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LihQxFL3IgOBGfFs6SgnutJhUXpUsVWwGQRfiQO9Cnk6BpmW6h9G_9yZV3U773FjLqhSEk5ucc0lyLsDTNNigZSJdUEp0XFra6Uh4FzRVmI6pEKrZ89t38viEv1mK5aVSX-VM2GQPPAF3hHKbyYH53unALaHWqeiHJIijuJLq6vOJnHcpmZpcvanmvZ5vyRCmjtbIVOU2GS21PJQg3cUeE1XD_t-pzF8PS_60Y1qJaHEDrs8Ksn0x9fwmXIn5Flydakp-uw10sXzfxq_z-dbcjrnFQV63q9SejpjGtjWbzR9HJLEzP-bVZ3sHThavP7w67ubCCJ1HgbXpfMB1KiUthj5Qn0RSLJDouWKWi8iTGryNUSekc-esjtqy3iHP04j8HVXP7sJBXuV4H1rMPkIgTDgkdu6tdPh4SZyTTlluUwP9FiTjZ9fwUrzik6m710yZCViDwJoKrLlo4Nnuny-TZ8ZfW78s2O9aFr_r-gKjwMxRYP4VBQ0cbkfOzJNwbVB7KCEVY6SBJ7vPOH3KnojNcXVe22hR8jLRwL1poHc9YUVbMkIbGPZCYK-r-1_yeFotujVKA0FkA8-3wfKjW3-G4sH_gOIhXKMlyonoKD-Eg83ZeXyEwmnjHtc58h25UBIE
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k1KQUHiBlYdPxL7hACxqpDggKi0N8vPNhIkZXer0n_P2PGmWh7NMXYkZ2bsbz6PPYPQq9gZr9pIsJdSYN4ailUgHHtFJdAx6X1O9vz5S3t0zD8txbJsuK3LscrtmpgXaj-6tEd-CEAiRSuBfr89-4lT1agUXS0lNG6iWyl1WbLqbtnNeywpisUbVe7KECYP14BX6U4ZTRU9pCD4YgePctr-f_mafx-Z_CNumuFocQ_dLX5k_W5S_H10IwwP0O2psuTlQ0QXy691-FVOuQ51P9Sg6nU9xvq0BzJbZ047nPQAZSvXD-MP8wgdLz5--3CES3kE7MDN2mDnYbWKUYmu8dRFESXzJDgumeEi8Cg7Z0JQEUDdWqOCMqyxgPY0AIoH2bDHaG8Yh_AU1cBBvCdMWIB37kxr4XEtsba10nATK9RshaRdyR2eSlh81zmGzaSeBKtBsDoLVl9U6PX8zdmUOePa3u-T7OeeKet1fjGuTnSZRBqoF2s75hqrPDeEGiuD66IglgKqKlahg63mdJmKa31lOBV6OTfDJEqRETOE8Tz3USKxM1GhJ5Oi55Gw5GEyQivU7ZjAzlB3W4b-NCfqVuAgCNJW6M3WWK6G9X9R7F__F8_QHZrslwhM-QHa26zOw3NwjDb2Rbb-3xlvCjw
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9RADA_nHYIv4rfVUyr4psXpfLQzj6u4HAv6oB7sW5nPu8LZyu4ep_-9memHrJ6CfWwzEJLM_JImkwC8DLV2qgqkcFKKgleaFsoTXjhFJYZj0rnU7PnDx-rklK_WYn0AdLoLk4r2U0vLdExP1WFvtgg08TIYjaM4pCDF1Q04iq3a0baPFovV59X8ZyXmrnipxhsyhMlrFu-hUGrWf52H-Weh5G_Z0gRCyztwe_Qe88XA71048N09uDnMk_xxH-hy_Sn338fa1i5vuxwVvM37kJ-3GMLmKZLtzloEsI1tu_6rfgCny_df3p0U41CEwqJztSuswzMqBCXq0lEbRJDMEW-5ZJoLz4OsrfZeBYRyY7TySrPSIMZTj9jtZckewmHXd_4x5Bh5OEeYMAjq3OrK4GMrYkxlpOY6ZFBOQmrs2DE8Dq64aFLmmslmEGyDgm2SYJurDF7Na74N_TL-Sf02yn6mjL2u04t-c9aMum8w4GJVzWxplOOaUG2kt3UQxFDEUsUyOJ4014wbcNug3yFFJRkjGbyYP-PWifkQ3fn-MtEoEWMykcGjQdEzJyz6lYzQDOo9E9hjdf9L156n9twK3QJBqgxeT8byi62_i-LJ_5E_hVs02jMRBeXHcLjbXPpn6B7tzPNxP_wEqfMJ2Q
  priority: 102
  providerName: Springer Nature
Title FXR expression in rats of hilar cholangiocarcinoma
URI https://link.springer.com/article/10.1038/s41598-022-12850-w
https://www.ncbi.nlm.nih.gov/pubmed/35610302
https://www.proquest.com/docview/2668568330
https://www.proquest.com/docview/2669502175
https://pubmed.ncbi.nlm.nih.gov/PMC9130506
https://doaj.org/article/6053673c1b9d4a02ab8ec7f50b229993
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFD70wmAvY_d664IHe9u8ybrY0sMYaWgogZbRLZA3I8lSG-icLUlp--93JDsZ2bIxvxgk2YhPR_6-Y0nnALzxpa5V4UlWSykyXmiaKUd4Visq0R2TdR2DPZ-eFSdjPpqIyQ6s0h11AC62unYhn9R4fvX-9sfdJ5zwH9sj4_LDAkkoHBSjIU2HFCS72YV9ZKYyZDQ47eR-G-ubKh5zfYQg7BmKCdqdo9n-mg2uiiH9t-nQP7dT_ramGqlq-BAedBoz7bdG8Qh2XPMY7rVZJ--eAB1OzlN32-2AbdJpk6IZLNKZTy-niEYaQWkupkhzczttZt_0UxgPj78OTrIudUJmUYItM1vjl8x7Jcq8ptYLL1lNnOWSaS4c97K02jnlkfCN0copzXKDSoA6ZHgnc_YM9ppZ4w4gRf-krgkTBqmfW10YvGxBjCmM1Fz7BPIVSJXt4oqH9BZXVVzfZrJqga0Q2CoCW90k8Hb9zPc2qsY_Wx8F7NctQ0TsWDCbX1TdBKvQLWNFyWxuVM01odpIZ0sviKHIuIolcLgauWplZRWqEykKyRhJ4PW6GidYWDXRjZtdxzZKBM9NJPC8Heh1T1hQn4zQBMoNE9jo6mZNM72MQbwVigdBigTerYzlV7f-DsWL_-jmS7hPgxETtHB-CHvL-bV7hcppaXqwW07KHuz3-6MvI7wfHZ99PsfSQTHoxb8RvThhfgKxVBdZ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYIL4k2gQJDgBFEdPxL7gBCvVUsfB9RKezN-titBUna3Wvqn-I2MnWSr5dFbc0ycyBnP-JvPY88g9CLU2skq4MIJwQtWaVJIj1nhJBFAx4RzKdnz3n61dcg-j_l4Df0azsLEbZXDnJgmatfauEa-CUAieCWAfr89-VHEqlExujqU0OjUYsefLYCyzd5sf4TxfUnI6NPBh62irypQWPBO5oV1YOQhSF6XjtjAg6AOe8sE1Yx7FkRttfcyABYao6WXmpYGQJJ4AD8vSgrfvYKuAvDiSPbqcb1c04lRM1bK_mwOpmJzBvgYz7CRWEFEcFwsVvAvlQn4l2_79xbNP-K0Cf5Gt9DN3m_N33WKdhut-eYOutZVsjy7i8ho_CX3P_tdtU0-aXJQrVnehvx4AuQ5Txy6OZoAdE7tpGm_63vo8FIEdx-tN23jH6IcOI9zmHID7gSzujJw2QobUxmhmQ4ZKgchKdvnKo8lM76pFDOnQnWCVSBYlQSrFhl6tXznpMvUcWHr91H2y5Yxy3a60U6PVG-0CqgerWpqSyMd05hoI7ytA8eGAIpLmqGNYeRUb_ozda6oGXq-fAxGGyMxuvHtaWojeWSDPEMPuoFe9oRGj5ZikqF6RQVWurr6pJkcp8TgEhwSjqsMvR6U5bxb_xfFo4v_4hm6vnWwt6t2t_d3HqMbJOoy5gVhG2h9Pj31T8Apm5unyRJy9PWyTe83pjZH6Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrUBcEG8CBYIEJ4jWsePEPiBEaVcthVVVUam34Ge7EiRld6ulf41fxziPrZZHb80xcSJnPONvPo89A_DSF8rK3JPECsGTLFc0kY5kiZVUIB0T1jbJnj-P853D7OMRP1qDX_1ZmLCtsp8Tm4na1iaskQ8RSATPBdLvoe-2Rexvjd6d_khCBakQae3LabQqsufOF0jfZm93t3CsX1E62v7yYSfpKgwkBj2VeWIsGrz3kheppcZzL5glzmSCqYy7zIvCKOekR1zUWkknFUs1AiZ1CIROpAy_ew3Wi8CKBrC-uT3eP1iu8IQYWpbK7qQOYWI4Q7QMJ9poqCciOEkWK2jYFA34l6f794bNP6K2DRiObsOtzouN37dqdwfWXHUXrrd1Lc_vAR0dHcTuZ7fHtoonVYyKNotrH59MkErHDaOujicIpFMzqerv6j4cXonoHsCgqiv3CGJkQNYSxjU6F5lRucbL5ETrXAuVKR9B2gupNF3m8lBA41vZRNCZKFvBlijYshFsuYjg9fKd0zZvx6WtN4Psly1Dzu3mRj09LjsTLpH4sbxgJtXSZopQpYUzhedEU8R0ySLY6Eeu7CaCWXmhthG8WD5GEw5xGVW5-qxpI3nghjyCh-1AL3vCgn_LCI2gWFGBla6uPqkmJ02acInuCSd5BG96Zbno1v9F8fjyv3gON9Dsyk-7470ncJMGVSY8odkGDObTM_cUPbS5ftaZQgxfr9r6fgOUPk2E
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FXR+expression+in+rats+of+hilar+cholangiocarcinoma&rft.jtitle=Scientific+reports&rft.au=Zhang%2C+Meng-Yu&rft.au=Luo%2C+Ming&rft.au=Wang%2C+Jie-Ping&rft.date=2022-05-24&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=8741&rft_id=info:doi/10.1038%2Fs41598-022-12850-w&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon